Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUIBRON-T vs AMINOPHYLLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular c AMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
FDA-approved: Treatment of symptoms and prevention of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD).,Off-label: Apnea of prematurity.,Off-label: Adjunctive therapy in chronic obstructive pulmonary disease (COPD).
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
Terminal elimination half-life: 7-9 hours in nonsmoking adults; prolonged in hepatic cirrhosis (up to 30 hours) or heart failure; shorter in smokers (4-5 hours) due to enzyme induction.
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Primarily hepatic metabolism via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Renal: 70% as metabolites (1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid) and 10% as unchanged drug in adults; biliary/fecal: minimal, <5%.
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
0.5 L/kg (0.3-0.7 L/kg); approximates total body water, indicating distribution into body tissues including the central nervous system.
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
Oral immediate-release: 96-100%; food may alter absorption rate of sustained-release (not extent).
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
GFR <10 m L/min: decrease dose by 50% and extend dosing interval to every 12-24 hours; monitor serum concentrations.
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: decrease dose by 50%; Child-Pugh Class C: decrease dose by 75% or consider alternative therapy.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Oral: 5 mg/kg every 6 hours for immediate-release; sustained-release not recommended for children <6 years; for ages 6-12: 10-20 mg/kg/day divided every 12 hours.
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Start at lowest effective dose (e.g., 200 mg every 12 hours) due to reduced clearance; monitor serum concentrations to avoid toxicity.
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
None for Quibron-T specifically. However, theophylline products carry warnings about the potential for serious adverse effects including seizures and arrhythmias, especially at serum levels above 20 mcg/m L.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
Serum theophylline levels must be monitored to avoid toxicity; therapeutic range is 10-20 mcg/m L.,Risk of seizures and cardiac arrhythmias, especially at supratherapeutic levels.,Use with caution in patients with peptic ulcer disease, seizure disorders, cardiac arrhythmias, and hepatic impairment.,Numerous drug interactions due to CYP1A2 inhibition or induction (e.g., cimetidine, fluoroquinolones, smoking).
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Hypersensitivity to theophylline or any component of the formulation.,Pre-existing cardiac arrhythmias (excluding bradyarrhythmias).,Active seizure disorder unless controlled with anticonvulsants.,Concurrent use with ephedrine or other sympathomimetics (relative).
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
High-fat meals may increase absorption, but consistent timing with food is key. Avoid excessive caffeine intake. Charcoal-broiled foods may increase metabolism, reducing effectiveness.
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
Theophylline (active ingredient of QUIBRON-T) is not considered a major teratogen. First trimester exposure is not associated with an increased risk of major congenital malformations based on population data. Second and third trimester use may be associated with transient neonatal effects such as irritability, jitteriness, tachycardia, and feeding intolerance due to transplacental passage. No specific structural teratogenicity has been established.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
Theophylline is excreted into breast milk in small amounts (M/P ratio ~0.6-0.7). Milk levels are about 60-70% of maternal serum levels. Breastfeeding is generally considered acceptable, but monitor the infant for signs of theophylline toxicity (irritability, jitteriness, poor feeding). Caution is advised in preterm or medically fragile infants.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
Theophylline clearance is decreased in the third trimester due to reduced hepatic metabolism and increased volume of distribution. Dose requirements may need reduction by 20-30% in the third trimester, with close monitoring of serum levels to maintain therapeutic range. Postpartum, clearance returns to prepregnancy levels within 2-4 weeks, requiring dose readjustment upward.
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
Quibron-T (theophylline) has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels due to variable metabolism. Cimetidine, ciprofloxacin, and fluvoxamine inhibit metabolism, increasing toxicity risk. Smoking and carbamazepine induce metabolism, reducing efficacy.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing products (coffee, tea, cola) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, tachycardia, or seizures.,Do not smoke or stop smoking suddenly; notify your doctor if you do.,Keep regular appointments for blood level monitoring.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUIBRON-T vs AMINOPHYLLINE, answered by our medical review team.
QUIBRON-T is a Xanthine Bronchodilator that works by Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular c AMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.. AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUIBRON-T and AMINOPHYLLINE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUIBRON-T is: Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.. The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUIBRON-T and AMINOPHYLLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUIBRON-T is classified as Category C. Theophylline (active ingredient of QUIBRON-T) is not considered a major teratogen. First trimester exposure is not associated with an increased risk of major congenital malformatio. AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.